Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CrownBio Agrees to be Acquired by JSR of Japan in $400 Million Deal

publication date: Dec 20, 2017

Crown Bioscience, a CRO with facilities in China, Taiwan, the US and Europe, will be acquired for $400 million by JSR Corporation of Japan. The offer was a 105% premium to the previous day's CrownBio stock price. With an extensive library of patient-derived xenograft (PDX) models, CrownBio offers translational programs for drug discovery and development in oncology, inflammation, cardiovascular and metabolic disease research. JSR is known as a materials sciences company, primarily for rubber-type products. It has recently expanded into life science through acquisitions. More details....

Stock Symbol: (TPEX: 6554)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China